Company intelligence / Profile preview
Apnimed, Inc.
Cambridge, Massachusetts, United Statesapnimed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Apnimed's lead candidate AD109 has completed Phase 2b trials with positive results and is currently in two Phase 3 clinical trials (SynAIRgy and LunAIRo) with topline data expected in Q2 and Q3 2025. The company has also begun a Phase 2A trial (RESTEADY) for SASS-001 with topline results expected in 1H 2026.[6][8]
- Therapeutic areas
- Pulmonology
- Modalities
- Small moleculesoral drug combinations
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Shionogi & Co., Ltd. (joint venture called Shionogi Apnimed Sleep Science or SASS)[6][10]
Beyond the preview
Go deeper on Apnimed, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Apnimed, Inc..